海外の治験の状況「1」での検索結果
259件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- A clinical trial to investigate the Efficacy and Safety of TD-1473 for the Treatment of Moderately-to-Severely Active Crohn's Disease
- Moderately-to-Severely Active Crohn’s Disease (CD) MedDRA version: 20.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Austria, Bulgaria, Croatia, France, Georgia, Germany, Greece, Hungary, Israel, Poland, Portugal, Romania, Russian Federation, Serbia, South Africa, Spain, Ukraine, United Kingdom, United States
- 2018-07-26
Authorised
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS 986165 in Subjects with Moderate-to-Severe Crohn's Disease
- Crohn's Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.0 Level: LLT Classification code 10011398 Term: Crohn's System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Australia, Brazil, Canada, Czech Republic, France, Germany, Hungary, Italy, Korea, Republic of, Mexico, Poland, Romania, Spain, Taiwan, United Kingdom, United States
- 2018-07-05
Authorised
- A non-blinded study of multiple doses of RZ358, in patients with low blood sugars due to genetic dysfunction resulting in over-secretion of insulin
- Hypoglycemia associated with congenital hyperinsulinism MedDRA version: 20.1 Level: LLT Classification code 10077227 Term: Hyperinsulinemic hypoglycemia System Organ Class: 10027433 - Metabolism and nutrition disorders MedDRA version: 20.0 Level: LLT Classification code 10020644 Term: Hyperinsulinism NOS System Organ Class: 10027433 - Metabolism and nutrition disorders MedDRA version: 20.0 Level: PT Classification code 10061211 Term: Hyperinsulinism System Organ Class: 10027433 - Metabolism and nutrition disorders MedDRA version: 20.1 Level: LLT Classification code 10022484 Term: Insulin hypoglycaemia System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Bulgaria, Croatia, Denmark, France, Germany, Israel, Netherlands, Serbia, Spain, Turkey, United Kingdom, United States
- 2016-11-08
Authorised
- A multicenter, open-label, single-arm study of pertuzumab in combination with trastuzumab and a taxane in first line treatment of patients with HER2- positive advanced (metastatic or locally recurrent) breast cancer
- Advanced breast cancer (metastatic or locally recurrent) MedDRA version: 20.0 Level: PT Classification code 10065430 Term: HER-2 positive breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Algeria, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Ecuador, Egypt, Estonia, European Union, Finland, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Lebanon, Lithuania, Mexico, Morocco, Netherlands, Pakistan, Peru, Poland, Portugal, Saudi Arabia, Serbia, Slovenia, Spain, Sweden, Turkey, Ukraine, United Arab Emirates, United Kingdom, Uruguay, Venezuela, Bolivarian Republic of
- 2012-01-16
Authorised
- Study to evaluate 2 types of treatment as first line treatment (masitinib + docetaxel or placebo + docetaxel ) in the treatment of patients with metastatic Castrate Resistant Prostate Cancer (mCRPC)
- metastatic Castrate Resistant Prostate Cancer (mCRPC).;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Austria, Belgium, Brazil, Canada, China, Czech Republic, Greece, Hong Kong, Hungary, India, Italy, Korea, Republic of, Malaysia, Mexico, Morocco, Peru, Philippines, Poland, Romania, Russian Federation, Singapore, Slovakia, South Africa, Spain, Tunisia, Ukraine, United Kingdom, United States
- 2014-03-26
Authorised
- A Randomized, Double-Blind Phase 1/2 Study of INCB039110 in Combination With Erlotinib Versus Erlotinib Alone in patients with Non–Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor–Activating Mutations
- Male or female individuals, aged 18 years or older who have Stage IIIB/IV or recurrent NSCLC. Subjects must have tumors that are positive for EGFR-activating mutation, namely, exon 19 deletions, exon 21 L858R mutations, or point mutations at position 719. Enrolled subjects must have a life expectancy of at least 12 weeks and have adequate liver, kidney, and bone marrow function. MedDRA version: 18.0 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.0 Level: PT Classification code 10029521 Term: Non-small cell lung cancer stage IIIB System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.0 Level: PT Classification code 10029515 Term: Non-small cell lung cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, European Union, Hong Kong, Israel, Korea, Republic of, Russian Federation, Taiwan, United Kingdom, United States
- 2015-09-25
Authorised
- A multi-part, clinical study testing the safety and effectiveness of cobimetinib in combination with paclitaxel as initial treatment for patients with triple-negative (HER2 negative, Estrogen receptor negative, and Progesterone receptor negative) breast cancer that has spread.
- Patients with metastatic or locally advanced, triple-negative adenocarcinoma of the breast that have not received prior systemic therapy for metastatic breast cancer.;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Czech Republic, France, Korea, Republic of, Spain, Taiwan, United Kingdom, United States
- 2014-10-20
Authorised
- A study comparing the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280586 versus commercially available rituximab in treating patients with low tumor burden follicular lymphoma in the first-line treatment setting.
- low tumor burden follicular lymphoma MedDRA version: 17.1 Level: HLGT Classification code 10025320 Term: Lymphomas non-Hodgkin's B-cell System Organ Class: 10005329 - Blood and lymphatic system disorders ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Belarus, Belgium, Brazil, Croatia, Egypt, France, Germany, Greece, India, Italy, Japan, Korea, Republic of, Lebanon, Mexico, Peru, Philippines, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States
- 2014-06-06
Authorised
- A study comparing the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280586 versus commercially available rituximab in treating patients with low tumor burden follicular lymphoma in the first-line treatment setting.
- low tumor burden follicular lymphoma MedDRA version: 20.0 Level: HLGT Classification code 10025320 Term: Lymphomas non-Hodgkin's B-cell System Organ Class: 10005329 - Blood and lymphatic system disorders ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Belarus, Belgium, Brazil, Croatia, Egypt, France, Germany, Greece, India, Italy, Japan, Korea, Republic of, Lebanon, Mexico, Peru, Philippines, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States
- 2014-06-04
Authorised
- A RANDOMIZED, OPEN-treatment, PHASE 2 STUDY OF THE IDO INHIBITOR INCB024360 compared with TAMOXIFEN FOR women WITH OVARIAN CANCER, that blood tests suggest is returning after COMPLETE REMISSION WITH FIRST-LINE CHEMOTHERAPY
- BIOCHEMICAL-RECURRENT-ONLY EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CARCINOMA, OR FALLOPIAN TUBE CANCER FOLLOWING COMPLETE REMISSION WITH FIRST-LINE CHEMOTHERAPY;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Canada, Russian Federation, Ukraine, United Kingdom, United States
- 2012-05-24
